REFERENCES
1. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512-22.
2. Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39 Suppl 1:19-31.
3. Sarantis P, Tzanetatou ED, Ioakeimidou E, et al. Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy. Am J Transl Res. 2021;13:13246-60.
4. Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol. 2008;24:349-56.
5. Gibson RN, Yeung E, Hadjis N, et al. Percutaneous transhepatic endoprostheses for hilar cholangiocarcinoma. Am J Surg. 1988;156:363-7.
6. Wu Q, Fan H, Lang R, et al. Overexpression of 14-3-3σ modulates cholangiocarcinoma cell survival by PI3K/Akt signaling. Biomed Res Int. 2020;2020:3740418.
7. Qi S, Yan H. Effect of percutaneous transhepatic cholangial drainag + radiofrequency ablation combined with biliary stent implantation on the liver function of patients with cholangiocarcinoma complicated with malignant obstructive jaundice. J Transl Res. 2021;13:1817-24.
8. Li S, Qian H, Peng Y, Jia H, Lin G. Differentiating peripheral cholangiocarcinoma in stages T1N0M0 and T2N0M0 from hepatic hypovascular nodules using dynamic contrast-enhanced MRI. Sci Rep. 2017;7:8084.
9. Zanuso V, Tesini G, Valenzi E, Rimassa L. New systemic treatment options for advanced cholangiocarcinoma. J Liver Cancer. 2024;24:155-70.
10. Hirohashi K, Uenishi T, Kubo S, et al. Macroscopic types of intrahepatic cholangiocarcinoma: clinicopathologic features and surgical outcomes. Hepatogastroenterology. 2002;49:326-9.
12. Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G, Heinemann V. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2009;69:259-70.
13. Su CH, Shyr YM, Lui WY, P'Eng FK. Hepatolithiasis associated with cholangiocarcinoma. Br J Surg. 1997;84:969-73.
14. Flavell DJ, Flavell SU. Opisthorchis viverrini: pathogenesis of infection in immunodeprived hamsters. Parasite Immunol. 1986;8:455-66.
15. Sripa B, Kaewkes S. Localisation of parasite antigens and inflammatory responses in experimental opisthorchiasis. Int J Parasitol. 2000;30:735-40.
16. Sripa B, Deenonpoe R, Brindley PJ. Co-infections with liver fluke and Helicobacter species: a paradigm change in pathogenesis of opisthorchiasis and cholangiocarcinoma? Parasitol Int. 2017;66:383-9.
18. Doherty B, Nambudiri VE, Palmer WC. Update on the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19:2.
19. Pinlaor S, Sripa B, Ma N, et al. Nitrative and oxidative DNA damage in intrahepatic cholangiocarcinoma patients in relation to tumor invasion. World J Gastroenterol. 2005;11:4644-9.
20. Sripa B, Brindley PJ, Mulvenna J, et al. The tumorigenic liver fluke Opisthorchis viverrini--multiple pathways to cancer. Trends Parasitol. 2012;28:395-407.
21. Lozano E, Sanchez-Vicente L, Monte MJ, et al. Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. Mol Cancer Res. 2014;12:91-100.
22. Park JH, Hong JY, Kwon M, et al. Association between non-alcoholic fatty liver disease and the risk of biliary tract cancers: a South Korean nationwide cohort study. Eur J Cancer. 2021;150:73-82.
23. Gatselis NK, Tepetes K, Loukopoulos A, et al. Hepatitis B virus and intrahepatic cholangiocarcinoma. Cancer Invest. 2007;25:55-8.
24. Matsumoto K, Onoyama T, Kawata S, et al. Hepatitis B and C virus infection is a risk factor for the development of cholangiocarcinoma. Intern Med. 2014;53:651-4.
25. Ralphs S, Khan SA. The role of the hepatitis viruses in cholangiocarcinoma. J Viral Hepat. 2013;20:297-305.
26. Kirstein MM, Vogel A. Epidemiology and risk factors of cholangiocarcinoma. Visc Med. 2016;32:395-400.
27. Ramírez-Merino N, Aix SP, Cortés-Funes H. Chemotherapy for cholangiocarcinoma: an update. World J Gastrointest Oncol. 2013;5:171-6.
28. Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39 Suppl 1:98-107.
29. Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist. 2016;21:594-9.
30. Rizzo A, Brandi G. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Expert Rev Gastroenterol Hepatol. 2021;15:483-5.
31. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology. 2005;41:5-15.
33. R. A. J. Freitas, Nanomedicine, Volume I: Basic Capabilities. 1st ed. Boca Raton: CRC Press; 1999.
34. Chamundeeswari M, Jeslin J, Verma ML. Nanocarriers for drug delivery applications. Environ Chem Lett. 2019;17:849-65.
35. Priem B, van Leent MMT, Teunissen AJP, et al. Trained immunity-promoting nanobiologic therapy suppresses tumor growth and potentiates checkpoint inhibition. Cell. 2020;183:786-801.e19.
36. Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T. Nanomedicine in cancer therapy. Signal Transduct Target Ther. 2023;8:293.
37. Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nat Rev Mater. 2021;6:351-70.
38. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9:1410.
39. Youn YS, Bae YH. Perspectives on the past, present, and future of cancer nanomedicine. Adv Drug Deliv Rev. 2018;130:3-11.
40. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2-25.
41. Masoudifar R, Pouyanfar N, Liu D, et al. Surface engineered metal-organic frameworks as active targeting nanomedicines for mono- and multi-therapy. Applied Materials Today. 2022;29:101646.
42. Doroudian M, Azhdari MH, Goodarzi N, O’Sullivan D, Donnelly SC. Smart nanotherapeutics and lung cancer. Pharmaceutics. 2021;13:1972.
43. Farjadian F, Faghih Z, Fakhimi M, Iranpour P, Mohammadi-Samani S, Doroudian M. Glucosamine-modified mesoporous silica-coated magnetic nanoparticles: A “Raisin-Cake”-like structure as an efficient theranostic platform for targeted methotrexate delivery. Pharmaceutics. 2023;15:2491.
44. Wang C, Zhang S. Advantages of nanomedicine in cancer therapy: a review. ACS Appl Nano Mater. 2023;6:22594-610.
45. Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol. 2016;13:750-65.
46. Rahimian S, Mirkazemi K, Kamalinejad A, Doroudian M. Exosome-based advances in pancreatic cancer: the potential of mesenchymal stem cells. Crit Rev Oncol Hematol. 2025;207:104594.
47. Yadav HK, Almokdad AA, shaluf SI, Debe MS. Polymer-based nanomaterials for drug-delivery carriers. nanocarriers for drug delivery. In: Mohapatra SS, Ranjan S, Dasgupta N, Mishra KR, Thomas S, editors. Nanocarriers for Drug Delivery: Nanoscience and Nanotechnology in Drug Delivery. Amsterdam: Elsevier; 2019. p. 531-56.
48. Wang JJ, Zeng ZW, Xiao RZ, et al. Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine. 2011;6:765-74.
49. Moghaddam FD, Zare EN, Hassanpour M, et al. Chitosan-based nanosystems for cancer diagnosis and therapy: stimuli-responsive, immune response, and clinical studies. Carbohydr Polym. 2024;330:121839.
50. Yang JI, Lee HL, Yun JJ, et al. pH and redox-dual sensitive chitosan nanoparticles having methyl ester and disulfide linkages for drug targeting against cholangiocarcinoma Cells. Materials (Basel). 2022;15:3795.
51. Lee HM, Jeong YI, Kim DH, et al. Ursodeoxycholic acid-conjugated chitosan for photodynamic treatment of HuCC-T1 human cholangiocarcinoma cells. Int J Pharm. 2013;454:74-81.
52. Kennedy L, Sandhu JK, Harper ME, Cuperlovic-Culf M. Role of glutathione in cancer: from mechanisms to therapies. Biomolecules. 2020;10:1429.
53. Correia JH, Rodrigues JA, Pimenta S, Dong T, Yang Z. Photodynamic therapy review: principles, photosensitizers, applications, and future directions. Pharmaceutics. 2021;13:1332.
54. Sadat Tabatabaei Mirakabad F, Nejati-Koshki K, Akbarzadeh A, et al. PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac J Cancer Prev. 2014;15:517-35.
55. Hines DJ, Kaplan DL. Poly(lactic-co-glycolic) acid-controlled-release systems: experimental and modeling insights. Crit Rev Ther Drug Carrier Syst. 2013;30:257-76.
56. Jeong YI, Kim DH, Chung CW, et al. Doxorubicin-incorporated polymeric micelles composed of dextran-b-poly(DL-lactide-co-glycolide) copolymer. Int J Nanomedicine. 2011;6:1415-27.
57. Omar AI, Plengsuriyakarn T, Chittasupho C, Na-Bangchang K. Enhanced oral bioavailability and biodistribution of atractylodin encapsulated in PLGA nanoparticle in cholangiocarcinoma. Clin Exp Pharmacol Physiol. 2021;48:318-28.
58. Sheoran S, Arora S, Samsonraj R, Govindaiah P, Vuree S. Lipid-based nanoparticles for treatment of cancer. Heliyon. 2022;8:e09403.
59. Allo G, Can AD, Wahba R, et al. Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers. Mol Clin Oncol. 2022;16:52.
60. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22(4 Suppl 11):3-10.
61. Gilbert JA, Salavaggione OE, Ji Y, et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res. 2006;12:1794-803.
62. Kim DH, Im BN, Hwang HS, Na K. Gemcitabine-loaded DSPE-PEG-PheoA liposome as a photomediated immune modulator for cholangiocarcinoma treatment. Biomaterials. 2018;183:139-50.
63. Choi KH, Chung CW, Kim CH, Kim DH, Jeong YI, Kang DH. Effect of 5-aminolevulinic acid-encapsulate liposomes on photodynamic therapy in human cholangiocarcinoma cells. J Nanosci Nanotechnol. 2014;14:5628-32.
64. Maphanao P, Phothikul Y, Choodet C, et al. Development and in vitro evaluation of ursolic acid-loaded poly(lactic-co-glycolic acid) nanoparticles in cholangiocarcinoma. RSC Adv. 2024;14:24828-37.
65. Alshammari BH, Lashin MMA, Mahmood MA, et al. Organic and inorganic nanomaterials: fabrication, properties and applications. RSC Adv. 2023;13:13735-85.
66. Paul W, Sharma C. Inorganic nanoparticles for targeted drug delivery. In: Sharma CP, editor. Biointegration of Medical Implant Materials (2nd ed). Cambridge: Woodhead Publishing; 2010. p. 204-35.
67. Tang T, Zheng JW, Chen B, et al. Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice. Hepatobiliary Pancreat Dis Int. 2007;6:303-7.
68. Ngernyuang N, Seubwai W, Daduang S, Boonsiri P, Limpaiboon T, Daduang J. Targeted delivery of 5-fluorouracil to cholangiocarcinoma cells using folic acid as a targeting agent. Mater Sci Eng C Mater Biol Appl. 2016;60:411-5.
69. Long C, Peng H, Yang W, et al. Targeted delivery of gemcitabine for precision therapy of cholangiocarcinoma using hyaluronic acid-modified metal-organic framework nanoparticles. ACS Omega. 2024;9:11998-2005.
70. Xia J, Kawamura Y, Suehiro T, Chen Y, Sato K. Carbon dots have antitumor action as monotherapy or combination therapy. Drug Discov Ther. 2019;13:114-7.
71. Chen M, Li Y, Ma N, Zang J. Mesenchymal stem cell-derived exosomes loaded with 5-Fu against cholangiocarcinoma in vitro. Mol Med Rep. 2022;25:213.
72. Chen Z, Kankala RK, Long L, Xie S, Chen A, Zou L. Current understanding of passive and active targeting nanomedicines to enhance tumor accumulation. Coord Chem Rev. 2023;481:215051.
73. Haaft BH, Pedregal M, Prato J, Klümpen HJ, Moreno V, Lamarca A. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives. Eur J Cancer. 2024;199:113564.
74. Zhang X, Zhang Y, Zhang Y, et al. Bio-engineered cell membrane nanovesicles as precision theranostics for perihilar cholangiocarcinoma. Biomater Sci. 2020;8:1575-9.
75. Liu Y, Wang Y, Sun S, et al. Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside. Exp Hematol Oncol. 2022;11:97.
76. Ahn S, Lee JC, Shin DW, Kim J, Hwang JH. High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. Sci Rep. 2020;10:12348.
77. Gondaliya P, Sayyed AA, Yan IK, Driscoll J, Ziemer A, Patel T. Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy. Mol Ther. 2024;32:2762-77.
78. Gabriel E, Gandhi S, Attwood K, Kuvshinoff B, Hochwald S, Iyer R. Gemcitabine and capecitabine for advanced biliary cancer. J Gastrointest Oncol. 2017;8:728-36.
79. Zhou Y, Xu L, Wang Z, et al. Sequentially targeting and intervening mutual polo-like kinase 1 on CAFs and tumor cells by dual targeting nano-platform for cholangiocarcinoma treatment. Theranostics. 2022;12:3911-27.
80. P. K. W. C. S. P. and K. V. P. Srikoon, “Deoxycholic acid-formulated curcumin enhances caspase 3/7-dependent apoptotic induction in cholangiocarcinoma cell lines,” Journal of Bacic and Applied Pharmacology, 2021;1. Available from: https://www.researchgate.net/publication/361332214_Deoxycholic_acid-formulated_curcumin_enhances_caspase_37-dependent_apoptotic_induction_in_cholangiocarcinoma_cell_lines (accessed on 2025-7-4).
82. Dreher KL. Health and environmental impact of nanotechnology: toxicological assessment of manufactured nanoparticles. Toxicol Sci. 2004;77:3-5.
83. Zielińska A, Costa B, Ferreira MV, et al. Nanotoxicology and nanosafety: safety-by-design and testing at a glance. Int J Environ Res Public Health. 2020;17:4657.
84. Donahue ND, Acar H, Wilhelm S. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv Drug Deliv Rev. 2019;143:68-96.
85. Knaapen AM, Borm PJ, Albrecht C, Schins RP. Inhaled particles and lung cancer. Part A: mechanisms. Int J Cancer. 2004;109:799-809.
86. Sharma N, Kurmi BD, Singh D, et al. Nanoparticles toxicity: an overview of its mechanism and plausible mitigation strategies. J Drug Target. 2024;32:457-69.
